ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ADMA BIOLOGICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.07+0.39 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $2.55B
- P/E (TTM)
- 15.8
- Dividend yield
- –
ADMA BIOLOGICS, INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADMA BioManufacturing [Member] | $123.64M | $113.74M | $123.15M | $134.19M | $121.95M | $113.72M | $111.79M | $117.72M | $106.18M | $80.11M | $73.83M | $66.57M | 99.4% | +1.4% |
| Plasma Collection Centers [Member] | $723.00K | $716.00K | $15.98M | $0 | $0 | $1.05M | $5.72M | $2.08M | $972.00K | $1.73M | $35.00K | $672.00K | 0.6% | – |
| Corporate [Member] | – | – | – | – | – | – | – | $36.00K | $36.00K | $36.00K | $36.00K | $36.00K | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADMA BioManufacturing [Member] | – | – | – | – | – | – | – | $48.35M | $46.71M | $28.70M | $20.95M | $15.02M | – |
| Plasma Collection Centers [Member] | – | – | – | – | – | – | – | -$1.76M | -$1.24M | -$1.06M | -$1.02M | -$683.00K | – |
| Corporate [Member] | – | – | – | – | – | – | – | -$6.95M | -$6.27M | -$5.82M | -$5.70M | -$5.65M | – |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $123.32M | $113.43M | $137.38M | $133.98M | $121.98M | $110.73M | $114.68M | $114.75M | $102.73M | $77.99M | $70.96M | $64.62M | 99.1% | +1.1% |
| International [Member] | $1.08M | $1.07M | $1.79M | $246.00K | $0 | $4.07M | $2.87M | $5.09M | $4.47M | $3.88M | $2.94M | $2.66M | 0.9% | – |
From the segment and revenue-disaggregation notes of Adma Biologics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.